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(e.g., heparin) that could potentially be a factor in the TCP. In this study, we attempted to 
elucidate the mechanism behind the development of TCP following exposure to a small 
peptide GPIIb-Illa antagonist, RPR109891 (Klerval). Methods: Blood samples from 102 
patients who developed TCP during 5 clinical trials of Klerval were analyzed and com- 
pared with samples from patients treated with Klerval who did not develop TCP, control 
patients exposed to placebo only, and normal controls. TCP was defined as a platelet 
count <100,000/mm3 or any drop >40% compared to baseline. ELISA and Western blot 
analyses were employed to assess for the presence of GPIIb-Illa antibodies and to deter- 
mine whether the presence of drug was necessary for antibody binding. Results: These 
assays found that 30% of TCP patients developed antibodies to GPIIb-Illa upon expo- 
sure to Klerval or its active metabofite, RPR109039. Also, more than half of the 
RPR109039-dependent antibodies generated had increased binding in the presence of 
drug. Western blot analyses confirmed binding of drug dependent antibodies to proteins 
in the GPIIb-Illa molecular weight range. Also, we found that seven patients (7%) with 
documented TCP had hepadn-dependent antibodies by the Asserechrom HPIA and GTI- 
PF4 ELISA assays. HIPA, which depends upon a platelet aggregation response, is an 
inconclusive test in the presence of GPIIb-Illa antagonists. Conclusion: This study indi- 
cates that RPR109039-dependent antibodies have an increased propensity to bind 
GPIIb-Illa ligand-induced binding sites (LIBS). When TCP occurs in patients receiving 
antiplatelet and anticoagulant herapies, all potential causative agents should be investi- 
gated. 
1177-92 Effect of Arterial Stiffness on Platelet Activation 
Fumivasu Yamaseki. Takashi Furuno, Masanod Nishinaga, Kyoko Sato, Dongmei Zhang, 
Miss Nakagawa, Tadashi Ueta, Takayuki Sato, Yoshinod Doi, Tetsuro Sugiura, Clinical 
Laborsto~ Medicine and Geriatrics, Physiology, Kochi Medical School, Nankoku, Kochi, 
Japan. 
Increased arterial stiffness is strongly associated with atherosclerosis, and platelet acti- 
vation is important initial step causing thrombotic events in patients with atherosclerosis. 
However, little is known about the effect of arterial stiffness on platelet activation. There- 
fore, this study was undertaken to evaluate the effect of arterial stiffness on platelet func- 
tion in 38 normal volunteers (20 males and 18 females), aged 23 - 77yrs (mean = 
49±15yrs). Arterial stiffness was assessed by measuring heart - dght brechial artery and 
heart - dght ankle pulse wave velocity (PWV, m/sac). Flow cytometric analyses were per- 
formed to evaluate platelet activation by measuring surface expression of P-selectin (%) 
and platelet-neutrophil complex (PNC, %) before and after activation by adenosine 
diphospate (ADP). 
Results (1) Each PWV had a significant positive correlation with age. The level of P- 
selectin and PNC also had a positive correlation with age. (2) Multiple regression analy- 
sis using 2 variables (age and each PWVs) showed that PNC and P-selectin were signif- 
icantly related to PWVs, but there were no significant relation with age. 
Concluelon The platelet activation was affected by arterial stiffness, which suggests that 
arterial stiffness may play an important role on thrombotic events in patients with athero- 
sclerosis. 
PNC PNC (ADP) PNC (ADP) P-selectin (ADP) 
heart-brachial artery PWV 2.86* 6.95** 0.75 6.54** 
Age 0.04 0.09 0.01 -0.60 
heart-right ankle PWV 0.79* 6.95** 0.28 1.75* 
Age 0.04 0.08 -0.004 -0.50 
*p<0.05, **p<0.01 
1177-93 Activated Factor Xll (FXlla) Predicts Recurrent 
Troponin-T Positive Cardiac Events Following an Acute 
Myocardial Infarction 
Heidi Grundt, E~yvind Hetland, Annette Knudsen, Dennis W. Nilsen, Central Hospital in 
Rogaland, Stavanger, Norwa~ 
Background: Activated factor Xll (FXlla) participates in inflammation, thrombosis and 
fibrinolysis, and is involved in vascular injury and repair. 
Methods: We compared the recurrency of TnT positive coronary events in the upper 
quartile of FXlla (> 2,23 ng/mL) to the eventrate below the 75% percentile during a 
median follow-up period of 1,5 years in patients with an acute myocardial infarction. Tis- 
sue factor (TF), fibrin monomer (FM) and ultrasensitive C-reactive protein (IICRP) were 
also evaluated in relation to prognosis. Blood samples were drawn 4-6 days after myo- 
cardial infarction in 300 patients. Analyses of FXlla, TF and FM were performed by 
ELISA-methodology. 
Results: Sixty-two patients suffered an adverse TnT positive event during the follow-up 
period. In the upper quartile of FXIla (n=74), 32,4% had a secondary TnT positive cardiac 
event, as compared to 16,9% in the three lower quartiles of FXIla (n=225), p=0,008. The 
relative risk of recurrent TnT positive cardiac events was 92% higher for participants with 
FXlla concentrations in the upper quartile as compared to those with concentrations 
below the 75% percentile (relative risk 1,92 [95% CI 1,24-2,98]). Moreover, significantly 
higher FXlta levels were observed among subjects with recurrent TnT positive events as 
compared to those without (p=0,039). Furthermore, TnT positive recurrent events 
occurred earlier in the upper as compared to the lower quadiles (log-rank test; p=O,003). 
Significant differences in recurrent events were not observed between upper and lower 
quadiles of TF, FM or pCRP. In the upper quartile of FXIla, 61,9% of patients with a previ- 
ous history of myocardial infarction suffered a secondary TnT positive event, as com- 
pared to an eventrate of 20,4% in patients with no history of myocardial infarction, 
p=0,0024, indicative of a joint effect of FXIla and previous myocardial infarction in risk 
stratification. 
Conclusion: FXIla predicts future TnT positive cardiac events related to coronary plaque 
rupture and subsequent thrombosis in survivors of myocardial infarction. 
1177-94 Effect of a Single Dose of Aspirin (325 mg) on Plstelets 
in Human Volunteers With Mul t ip le  Risk Factors for 
Coronary Artery Disease 
Alexei I. Malinin, Kevin P. Callahan, Marcus E. McKenzie, Victor L Serebruany, Sinai 
Hospital, Johns Hopkins Universi~ Baltimore, Maryland. 
Background: Aspirin is beneficial for treatment and prevention of coronary artery disease, 
There are some data suggesting that platelet inhibition by aspirin is not exclusively 
related to prostaglandin blockade. We sought to determine how one pill of non-enteric 
coated aspirin (325-mg) affects human platelets in subjects with multiple risk factors for 
coronary artery disease. Methods: Data from 63 volunteers were analyzed. Platelets 
were assessed twice at baseline (pre-aspirin), and after 3-24 hours (post-aspirin). We 
employed 5~M epinephrine-induced conventional aggregometry, closure time with epi- 
nephrine/collagen cadddge by PFA-100~ (Dade-Behring, Inc), and aspirin reaction units 
stimulated by propyl gallat with Ultegre~ (Accumetdcs, Inc.) for measuring platelet func- 
tion, The expression of platelet receptors was determined by using the following mono- 
clonal antibodies: CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CDI07a, and 
CD151. PAC-1 was used to measure fibdnogen-platelet binding. Platelet-leukocyte for- 
mation was detected utilizing dual antibodies for a pan-platelet marker CD151, and 
CD14, a monocyte/macrophage marker. Results: A single tablet of aspirin significantly 
reduced platelet-rich plasma aggregation, and resulted in the decrease of aspirin reduc- 
tion units, and prolongation of the closure time. High correlation (r2=0.73-0.86) between 
platelet analyzers readings and aggregometry was observed. One pill of aspirin moder- 
ately inhibits expression of various surface platelet receptors measured, and such inhibi- 
tion reached significance (p<0.05) for CD31, CD41, CD42, CD62p, and CD151, and 
PAC-1. Conclusion: Aspirin exhibits direct effect on selective major platelet receptors 
challenging the postulate of exclusive prostanoid inhibition via platelet cyclooxygenase-1 
blockade. Apparently, independent additional mechanisms of aspidn anti-platelet proper- 
ties may be involved in high-risk patients for the development of coronary artery disease. 
Ultegra® Analyzer with a novel cartridge could be successfully used in clinical practice 
for monitoring of aspirin therapy efficacy, and early detection of aspirin resistance. 
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1178-82 Inotropic Effects of Selective ET-B Receptor Stimulation 
and Its Modulation by Endocardial Endothelium, NO, 
and Proataglandins 
Adelino F. Leite-Moreira, Carmen Brds-Silva, Carla A. Pedrosa, DpL Physiology, Faculty 
of Medicine, Porto, Portugal. 
Background. Endotbelin-1 (ET-1) is an endogenous peptide whose effects are mediated 
by ET-A and ET-B receptors. ET-A are responsible for the vasoconstrictor, positive ino- 
tropic and growth promoting properties of ET-1, while ET-B for its vasodilator and anti- 
mitogenic effects, presumably due to NO release, This study investigated the less well- 
known inotropic effects of selective ET-B stimulation, 
Methods. The study was performed in papillary muscles from New Zealand rabbits 
(n=25) and Wistar rats (n=33) (Krebs-Ringer; 1.8 mM Ca2+; 35°C). Effects of selective 
ET-B receptor activation by Sarafotoxin $6c (SRTX-c; 0.21~M) were evaluated in the 
absence (rabbit n=7; rat n= 8) and in the presence of NG-nitro-L-Arginine (L-NA; 90~M; 
rabbit n= 6; rat n=8), Indomethacin (INDO; I~M; rabbit n=6; rat n=8) and in muscles with- 
out endocardial endothelium (EE; rabbit n=6;rat n=9). Parameters for isometric contrac- 
tions included: active tension (AT) and peak rate of tension development (dT/dtmax). 
Only significant results (mean±SEM, p<0.05) are given, expressed as % change from 
baseline, 
Results. SRTX-c induced a negative inotropic effect, reducing AT (rabbit: 8.3±2.1%; rat: 
9.8±3.7%) and dT/dtmax (rabbit: 8.6±5.6%; rat: 8.9-z3.3%). In the rat, this effect was not 
influenced by L-NA (AT decreased 9.7+~?..8% and dT/dtmax 8.6+~2.9%), was blunted by 
INDO (AT decreased non-significantly 5.5+3,1% and dT/dtmax 7.2_+4.1%) and almost 
abolished when the EE was removed (AT decreased non-significantly 3.8±3.5% and dT/ 
dtmax 3.9±.3.5%). tn the rabbit, the negative inotropic effect of SRTX-c was reversed by 
L-NA (AT increased 22.8+_2,9 % and dT/dtmax 20.1+~?.,1%), by INDO (AT increased 
18,0!-_4.4 % and dT/dtmax 18.9±4.0%) and by EE removal (AT increased 35.2+11.7% 
and dT/dtmax 29.5±7.9%). 
Conclusions. Selective ET-B stimulation induces a negative inotropic effect both in rab- 
bit and rat myocardium, which is modulated by the EE. Damaging the EE reverses this 
effect in the rabbit and almost abolishes it in the rat. In the rabbit, EE modulation is pre- 
sumably mediated by NO and prostaglandins, while in the rat it seems to be only influ- 
enced by prostaglandins but not by NO. 
1178-83 Cocaine Increases Cardiac Ventricular Myocyte Protein 
Content by Protein Kinase C Dependent Mechanisms 
Robed J. Hennino, Yong Xian 9 Li, Adam Leon, University of South Florida College of 
Medicine, Tampa, Florida, James A, Haley VA Hospital, Tampa, Florida. 
BACKGROUND: Six million Americans regularly use cocaine, Chronic cocaine users 
have a 69% increase in LV muscle mass without associated increases in arterial pres- 
sure, heart rate, renin, aldosterone, norepinephrine, or cortisol. We determined whether 
cocaine directly increases the protein content of adult ventricular myocytes and if protein 
kinase C (PKC) is important in this process. METHODS: Adult rat cardiomyocytes were 
JACC 
isolated and grown in cultures. In 12 experiments, cocaine, 10 -8 to 10 -6 M or vehicle-con- 
trol, in the absence or presence of metoprolol or phentolamine, was added to each cul- 
ture on day 2 and cells harvested on day 5. In 12 separate experiments, cocaine 10 -6 M, 
cocaine 10-6 M plus the PKC inhibitor bisindolylmaleimide, 10-6 M, or vehicle were added 
to each culture for a mean of 5 mine. then cells were harvested. We determined myocyte 
total protein and myosin heavy chain protein content, and the presence of PKC isozymes 
in cytosol and particulate (nuclear) fractions. PKC translocation from cytosol to particu- 
late fractions indicates PKC activation. RESULTS: Cocaine, 10 -6 M, increased myocyte 
protein content by 28% (p<0.001) and fetal ~-myosin heavy chain protein content/cell by 
82% (p<0.001) but decreased adult (x-myosin heavy chain protein content. Neither beta- 
nor alpha-adrenergic blockade inhibited this process. We found that adult ventricular 
myocytes contain alpha (~), delta, epsilon, and zeta PKC isozymes. Cocaine, 10 "s M, 
increased c~PKC by 37% (p<0.001) in the particulate fraction, decreased (xPKC in the 
cytosol fraction, and increased myocyte protein content by 22% (p<0.01) . In separate 
experiments, c~PKC stimulated rat myocyte ~-myosin heavy chain promoter and 
increased ~-myosin heavy chain protein transcription 3-fold. Addition of bisindolylmaleim- 
ide, 10 -6 M, to myocyte cultures, prevented the cocaine-induced translocation of ~PKC to 
the particulate fraction and cocaine-induced increase in myocyte protein content. CON- 
CLUSIONS: Cocaine increases myocyte protein content by PKC mechanisms. Protein 
kinase C translocation and nuclear transcription factor phosphorylation are important in 
the cardiac hypertrophy and myopathy resulting from chronic cocaine use. 
1178-84 Cardiac Fibroblast Actions of Cardiotrophin-1 and Its 
Receptor Complex with Crosstalk With the Endothelin 
System In Vitro: Modulation by Early Dilated 
Cardiomyopathy 
Toshihiro Tsuruda, Brenda Huntley, Guido Boerrigtar, Alessandro Cataliotti, Shang C. 
Lee, Horng H. Chen, Lisa C. Costello, John C. Burnett, Jr., Mayo Clinic, Rochester, 
Minnesota. 
Background: The cardiac interstitium and its tibrillar collagen matrix play a critical role in 
determining cardiac function and structure. Cardiotrophin-1 (CT-1) is a potent hyper- 
trophic factor in cardiomyocytes, and its gene expression is up-regulated in severe heart 
failure. To date, the role of CT-1 on cardiac fibroblast function is unknown. This study was 
designed to clarify the actions of CT-1 with its receptors, glycoprotein 130 (gp130) and 
leukemia inhibitory factor receptor (LIFR), and elucidate possible crosstalk with the 
endothelin-1 (ET-1)/endothelin type A (ETA) receptor axis in adult canine cardiac fibro- 
blasts (CCF). In addition, we investigated the modulation of these proteins in ventricular 
myocardium from normal dogs and those with tachycardia-induced early dilated cardi- 
omyopathy (EDCM). 
Methods and Results: We assessed DNA synthesis of cardiac fibroblasts by [3H]thymi- 
dine incorporation into cells. Recombinant CT-1 (P<0.01) stimulated DNA synthesis 
between 10 "11 and 10-6 mol/L, with maximal effect at 10-6 mol/L (186%). Administration 
(10 pJmL) of gp130 or LIF receptor antibody (P<0.01) completely inhibited not only CT-1 
stimulated DNA synthesis in CCF but also ET-1 stimulated DNA synthesis. By contrast, 
10 -5 mol/L BQ123, an ET A receptor antagonist, abolished CT-1 as well as ET-1 stimu- 
lated DNA synthesis. Western Blotting showed that 10 .7 mol/L ET-1 stimulated the trans- 
location of LIFR from cytosol to the cell membrane. CT-1 and gp130/LIFR in a canine 
model of EDCM produced by progressively increasing pacing rates (180 to 200 bpm for 
approximately 14-20 days) were characterized by immunohistochemistry as compared to 
normal ventricular myocardium. Staining revealed that CT-1 and gp130 were decreased 
and LIFR were enhanced. 
Conclusions: This study demonstrates that CT-1 and its receptor complex are function- 
ally important and contribute to cardiac fibroblast activation. In addition, CT-1 stimulation 
in CCF involves crosstalk with the gp13O/LIF receptor complex and the ET-1/ET A recep- 
tor. The in vivo findings of decreased CT-1 protein and gp130 in a model of EDCM also 
suggest that an impairment of this axis could contribute to progressive cardiac dilatation. 
1178-85 Oxidized LDL Through LOX-1 Increases the Expression 
of Angiotensin Converting Enzyme in Human Coronary 
Artery  Endothelial Cells 
Robin M Sinah, Dayuan Li, Ling Liu, Hongjiang Chen, Francesco Romeo, Nelly Kazzaz, 
Ballkrishna M. Singh, Jawahar L, Mehta, University of Arkansas for Medical Sciences, 
Little Rock, Arkansas, Central Arkansas Veterans Healthcare System, Little Rock, 
Arkansas. 
Background and objectives: Abnormalities of both renin-angiotensin system (RAS) and 
lipide play a critical role in the pathogenesis of cardiovascular diseases. Our previous 
studies demonstrate that angiotensin II (Ang II) and oxidized low-density lipoprotein (ox- 
LDL) in a synergistic fashion induce vascular endothelial injury. This study was con- 
ducted to examine the modulation of ACE gene expression by ox-LDL in human coronary 
artery endothelial cells (HCAECs). 
Methods and results: HCAECs were cultured and incubated with ox-LDL (10 to 80 rag/ 
ml) for 3-24 hours. Ox-LDL increased the expression of mRNA (determined by semi- 
quantitative RT-PCR) and prote!n (determined by Western blot) of ACE in a concentra- 
tion- and time-dependent fashion. Native-LDL had no effect on the expression of ACE 
gene. These effects of ox-LDL was mediated by its endothelial receptor LOX-1, since 
pretreatment of HCAECs with the blocking antibody to LOX-1 (10 mg/ml) prevented the 
expression of ACE (P<0,01 vs. control) in response to ox-LDL. In parallel experiments, 
HCAECs were treated with the mitogen-ectivated protein kinase (MAPK) inhibitor 
(PD98059, 10 raM) for 30 rain and then exposed to ox-LDL MAPK inhibitor blocked the 
effects of ox-LDL on the expression of ACE (P<0.01 vs. ox-LDL group). In other experi- 
ments, we observed that pretreatment of HCAECs with simvastatin (10 mM) attenuated 
ox-LDL-induced ACE gene expression (P<0.01 vs. ox-LDL alone). 
Conclusions: These observations provide a novel mechanism of interaction between 
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RAS and ox-LDL (upregulation of ACE via LOX-1 activation). MAPK activation plays a 
critical signal transduction role in this process. Lastly, statins can modulate ACE expres- 
sion by ox-LDL. 
1178-86 Activation of the Tissue Endothelin System in Severe 
Polyglobulis 
Matthias Hermann. Frank Ruschitzka, Thomas Quaschning. Sidney Shaw, Henning 
Morawietz, Berthold Hocher, Max Gassmann, Thomas F. L~scher, Cardiovascular 
Research, University of Zuerich, Zuerich, Switzerland, Cardiovascular Center, University 
Hospital Zuerich, Zuerich, Switzerland. 
We generated a novel erythropoietin overexpressing mouse, which reaches adulthood 
despite hematocrit levels of about 80%. The role of endothelin in severe polyglobulia, 
however, remains still to be determined. In this novel transgenic model of severe poly- 
globulia, we analyzed endothelin-1 (ET-1) promoter activity, ET-1 immuno-histochemis- 
try, ET-l-protein tissue levels, ETA/B-receptor subtype mRNA expression and vascular 
reactivity to ET-I. 
Transgenic polyglobulic animals xhibited increased ET-1 promoter activity (P<0.05 vs. 
wildtype controls) and ET-1 tissue levels in heart (265±36 vs. 165±25 pg/mg tissue; 
P<0.05 for left ventricle and 320±38 vs.170±31 pg/mg tissue; P<0.O5 for right ventricle, 
respectively), renal cortex (793±67 vs. 395±32 pg/mg tissue; P<0.01), and aorta (2.2-.~0.3 
vs. 0.5±0.1 pg/mg tissue; P<0.01). Aortic ET receptor subtype mRNA expression was 
enhanced in transgenic animals (1.5±0.2 vs.1.0±0.2 RU for ETA; 1.2¢0.1 vs. 0.7±0.1 RU 
(P<0.05) for ETB receptor mRNA, respectively). Vascular reactivity to ET-1 was reduced 
(35±5% vs. 78¢7% of KCI; P<0.05), but increased by preincubation with the nitric oxide 
(NO) synthase inhibitor L-NAME (P<0.05), thus indicating that the vascular effects of ET- 
1 are offset by NO, the endothelial counterpart of ET-1, in vivo. Correspondingly, treat- 
ment with the ETA receptor antagonist darusentan prolonged survival of transgenic mice 
exposed to the NO synthase inhibitor L-NAME (p<0.01). We here for the first time dem- 
onstrate that polyglobulia induces a marked activation of the tissue endothelin system. 
Since treatment with darusentan prolonged survival after acute NO blockade, activation 
of the tissue endothelin system may thus advance as a new target in the treatment of 
cardiovascular disease associated with severe polyglobulia. 
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1179-75 Calculated LDL Cholesterols Frequently Underestimate 
Directly Measured LDL Determinations in Patients With 
Triglyceride Levels _<400 mg/dL 
Dennis A. Tiohe. Ira S. Ockene, George Reed, University of Massachusetts Medical 
Center, Worcester, Massachusetts. 
Elevated low density lipoprotein (LDL) cholesterol is a risk factor for development of cor- 
onary artery disease (CAD). Recent guidelines detail specific LDL cutpoints for risk 
assessment. In clinical practice LDL concentration is usually calculated (C-LDL) from the 
Friedewald formula (FF). Methods: To assess the accuracy of C-LDL by the FF com- 
pared to directly measured LDL (D-LDL), we analyzed 1618 fasting lipid samples 
obtained in 661 patients (pts) [mean age 46+12 yr, 52% female] without overt CAD. Pts 
with triglycerides (TG) >400 mg/dL were excluded. Results: Mean total cholesterol was 
246+41, HDL 52+15, and TG 147+77 mg/dL. C-LDL and D-LDL were significantly differ- 
ent (165_+34 vs 187+41, p<0.0001) and D-LDL exceeded C-LDL in 93% of measure- 
ments. Although C-LDL and D-LDL were related (r=0.90), the discrepancy between C- 
LDL and D-LDL (LDL-difference) increased linearly with TG (r=0.67, figure) and clinically 
important differences existed at normal or slightly elevated TG levels. Regression analy- 
sis indicated that this LDL difference increased by 17 mg/dL for every 100 mg/dL TG 
increase. Conclusions: (1) Significant differences between C-LDL and D-LDL existed in 
pts with TG <400 mg/dl. (2) These differences were related to TG. (3) C-LDL by the FF 
may be unreliable to accurately categorize cardiac risk. 
